Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900046 | 0.91 | KMT2A (0.47) | PTGIRPTGDRKMT2AFABP5FABP7 | |
| SCHEMBL1622971 | 0.89 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL3818461 | 0.89 | EPHX2 (0.44) | PTGIRKMT2AFABP5FABP7CASP3 | |
| SCHEMBL3659499 | 0.88 | PTGIR (0.45) | PTGIRPTGDRKMT2AFABP5FABP7 | |
| SCHEMBL5847171 | 0.88 | KMT2A (0.43) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL3820525 | 0.88 | FABP5 (0.46) | PTGIRPTGDRKMT2AFABP5FABP7 | |
| SCHEMBL3817315 | 0.88 | PTGIR (0.43) | PTGIRPTGDRKMT2AFABP5FABP7 | |
| SCHEMBL3814178 | 0.87 | FABP5 (0.41) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL3811371 | 0.87 | PTGIR (0.46) | PTGIRKMT2AFABP5FABP7CASP3 | |
| SCHEMBL27696345 | 0.86 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791837-B1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-7371869-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1791837-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. Hoffmann-Roche AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006029862-A1 | SUBSTITUTED HYDANTOINS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
| US-20060063814-A1 | Substituted hydantoins | GOODNOW ROBERT A JR | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063814-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | PTGIR 1610/4885PTGDR 622/4885KMT2A 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.